WO2023062359A3 - Novel viral regulatory elements - Google Patents

Novel viral regulatory elements Download PDF

Info

Publication number
WO2023062359A3
WO2023062359A3 PCT/GB2022/052577 GB2022052577W WO2023062359A3 WO 2023062359 A3 WO2023062359 A3 WO 2023062359A3 GB 2022052577 W GB2022052577 W GB 2022052577W WO 2023062359 A3 WO2023062359 A3 WO 2023062359A3
Authority
WO
WIPO (PCT)
Prior art keywords
regulatory elements
viral regulatory
nucleotide sequences
novel viral
viral vectors
Prior art date
Application number
PCT/GB2022/052577
Other languages
French (fr)
Other versions
WO2023062359A2 (en
Inventor
Daniel Farley
Jordan Wright
Cristina NOGUEIRA
Original Assignee
Oxford Biomedica (Uk) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica (Uk) Limited filed Critical Oxford Biomedica (Uk) Limited
Publication of WO2023062359A2 publication Critical patent/WO2023062359A2/en
Publication of WO2023062359A3 publication Critical patent/WO2023062359A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Abstract

The present invention relates to novel nucleotide sequences, and to viral vectors or cells comprising such nucleotide sequences. The invention also relates to viral vector production systems, and methods for producing viral vectors using the nucleotide sequences, viral vectors, or cells described herein. Methods for identifying sequences that improve transgene expression in a target cell are also provided herein.
PCT/GB2022/052577 2021-10-12 2022-10-12 Novel viral regulatory elements WO2023062359A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2114534.7A GB202114534D0 (en) 2021-10-12 2021-10-12 Novel viral regulatory elements
GB2114534.7 2021-10-12

Publications (2)

Publication Number Publication Date
WO2023062359A2 WO2023062359A2 (en) 2023-04-20
WO2023062359A3 true WO2023062359A3 (en) 2023-06-15

Family

ID=78595158

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2022/052577 WO2023062359A2 (en) 2021-10-12 2022-10-12 Novel viral regulatory elements

Country Status (2)

Country Link
GB (1) GB202114534D0 (en)
WO (1) WO2023062359A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021181108A1 (en) * 2020-03-13 2021-09-16 Oxford Biomedica (Uk) Limited Lentiviral vectors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5512421A (en) 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US5723315A (en) 1996-08-23 1998-03-03 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
DE69729007T2 (en) 1996-08-07 2005-04-07 Darwin Discovery Ltd., Slough HYDROXAMIC ACID AND CARBOXYLIC DERIVATIVES WITH MMP AND TNF HEMMENDER EFFECT
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
HUP0000421A2 (en) 1996-10-17 2000-06-28 Oxford Biomedica (Uk) Limited Retroviral vectors
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
DK1895010T3 (en) 1997-12-22 2011-11-21 Oxford Biomedica Ltd Vectors based on viruses for infectious horse anemia (eiav)
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
GB9904905D0 (en) 1999-03-03 1999-04-28 Oxford Biomedica Ltd Cells
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
US7419829B2 (en) 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
EP2348119B1 (en) 2002-02-01 2017-04-26 Oxford BioMedica (UK) Limited Multicistronic lentiviral vector
JP4992032B2 (en) 2002-09-03 2012-08-08 オックスフォード バイオメディカ（ユーケー）リミテッド Retro virus vector
FR2872170B1 (en) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse NON-INTERACTIVE AND NON-REPLICATIVE LENTIVIRUS, PREPARATION AND USES
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
GB0526211D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
ES2618851T3 (en) 2008-06-18 2017-06-22 Oxford Biomedica (Uk) Limited Purification of retroviral vectors
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
ES2951857T3 (en) 2017-12-22 2023-10-25 Oxford Biomedica Ltd retroviral vector
US20220348958A1 (en) 2019-07-23 2022-11-03 Oxford Biomedica (Uk) Limited Enhancing Production of Lentiviral Vectors
KR20220097492A (en) 2019-11-12 2022-07-07 옥스포드 바이오메디카(유케이) 리미티드 production system
WO2021160993A1 (en) 2020-02-13 2021-08-19 Oxford Biomedica (Uk) Limited Production of lentiviral vectors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021181108A1 (en) * 2020-03-13 2021-09-16 Oxford Biomedica (Uk) Limited Lentiviral vectors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BORDEN KATHERINE ET AL: "mRNA Export and Its Dysregulation in Disease", NUCLEAR-CYTOPLASMIC TRANSPORT, 28 July 2018 (2018-07-28), pages 179 - 204, XP093013641, DOI: 10.1007/978-3-319-77309-4_8 *
HYRINA ANASTASIA ET AL: "A Genome-wide CRISPR Screen Identifies ZCCHC14 as a Host Factor Required for Hepatitis B Surface Antigen Production", CELL REPORTS, vol. 29, no. 10, 1 December 2019 (2019-12-01), US, pages 2970 - 2978.e6, XP093014090, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2019.10.113 *
LEI HAIXIN ET AL: "Evidence that a consensus element found in naturally intronless mRNAs promotes mRNA export", NUCLEIC ACIDS RESEARCH, vol. 41, no. 4, 28 December 2012 (2012-12-28), GB, pages 2517 - 2525, XP055980493, ISSN: 0305-1048, DOI: 10.1093/nar/gks1314 *

Also Published As

Publication number Publication date
WO2023062359A2 (en) 2023-04-20
GB202114534D0 (en) 2021-11-24

Similar Documents

Publication Publication Date Title
WO2019236599A3 (en) High-throughput single-cell transcriptome libraries and methods of making and of using
WO2014202616A3 (en) Rasamsonia gene and use thereof
MX2008000200A (en) Polynucleotides encoding isoprenoid modifying enzymes and methods of use thereof.
WO2018146588A8 (en) Synp88, a promoter for the specific expression of genes in retinal ganglion cells
WO2020097372A8 (en) Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear
WO2016049258A3 (en) Functional screening with optimized functional crispr-cas systems
WO2020086144A3 (en) APPLICATIONS OF CRISPRi IN HIGH THROUGHPUT METABOLIC ENGINEERING
GB2325003A (en) Rectroviral vectors
WO2020219682A3 (en) Gene knock-outs to improve t cell function
IL309801A (en) Using nucleosome interacting protein domains to enhance targeted genome modification
MX2020005458A (en) Alpha-amylase variants and polynucleotides encoding same.
MX2021014525A (en) Modified adenoviruses.
MX2020012332A (en) Codon-optimized acid î‘lpha-glucosidase expression cassettes and methods of using same.
WO2015181119A3 (en) Lipase variants and polynucleotides encoding same
CA2498668A1 (en) Generation of plants with improved drought tolerance
WO2023062359A3 (en) Novel viral regulatory elements
WO2017058884A3 (en) Modified bacterial protein expression system
EP3950939A3 (en) Lipase variants and polynucleotides encoding same
MX2022002956A (en) Systems and methods for protein expression.
WO2021016227A8 (en) Synthetic genetic elements for biomanufacture
WO2020210480A3 (en) Factor h vectors and uses thereof
WO2023039534A3 (en) Compositions comprising a cas12i polypeptide and uses thereof
WO2020087076A8 (en) Methods and uses of introducing mutations into genetic material for genome assembly
WO2002086112A3 (en) Nucleic acid molecules encoding starch degrading enzymes
WO2023049421A3 (en) Ubiquitin variants with improved affinity for 53bp1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22793794

Country of ref document: EP

Kind code of ref document: A2